Allianz Asset Management Gmb H Vaxcyte, Inc. Transaction History
Allianz Asset Management Gmb H
- $72.3 Billion
- Q4 2024
A detailed history of Allianz Asset Management Gmb H transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 6,800 shares of PCVX stock, worth $517,752. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,800
Previous 7,500
9.33%
Holding current value
$517,752
Previous $856,000
35.05%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$911 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$805 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$757 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$662 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$473 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.52B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...